Warapen Treekit

[NEJM @NEJM]

Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) https://t.co/y4G27hfORg

#ASCO26 | @ASCO

[Mark Lewis, MD, FASCO @marklewismd]

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer

Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived

#ASCO26

[Dr. Anthony Letai @NCIDirector]

#PancreaticCancer remains a challenge. Targeting #KRAS was a key step—but responses are often temporary. New @theNCI-supported work identifies a protein that may drive resistance, opening a path to extend treatment benefit in pancreatic and other cancers https://t.co/HAeCYUMuYW

[Warapen Treekit @warapen]

@Aiims1742 @MDAndersonNews Thank you, Dr. Maitra for your longstanding support!

[Warapen Treekit @warapen]

Proud to share our @NaturePortfolio research article: "RASH3D19 as a mediator of RAS pathway activation through a positive feedback loop in KRAS-mutant cancer", now out in Nature Cell Biology.

Read it here: https://t.co/iKHqCS0qJU

https://t.co/fXid5iXPyU

[Anirban Maitra @Aiims1742]

Congratulations to Subrata Sen & team
@MDAndersonNews for their @NatureCellBio paper:
RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer
https://t.co/EIa1C4TPPi

[Mammary Cell News @MammaryCell]

In this @BrJCancer study, scientists from @MDAndersonNews discover that epigenetic activation of 🧦 SOX11 drives 🚙 recurrence of ductal carcinoma in-situ (DCIS) and progression 📈 to invasive cancer.

😎 Check it out: https://t.co/N8gmQ2DRWT

[Science Signaling @scisignal]

Examining the role of eEF1A2 in cancer, researchers at @MDAndersonNews find the factor normally interacts with the tumor suppressor #PTEN to repress the #CellCycle and degrade Aurora-A, but that the latter is more abundant in #BreastCancer tissues. https://t.co/H2uQHjaCc6

[Roel Verhaak @roelverhaak]

The most important paper of 2024 🤯

[Itai Yanai @ItaiYanai]

A riddle for scientists: what is (1) better than publishing in Nature, (2) more evil than reviewer 2, (3) the postdocs have it, (4) the Nobel prize winners need it, and (5) if you publish it you perish?

[Dr. Ron DePinho @RonDePinho]

do athletes live longer than sedentary folks?

[Gastroenterology @AGA_Gastro]

Calling all coffee enthusiasts! Exciting research reveals how caffeine influences #intestinal tumor initiation. Interested in learning more? Click the link ➡️ https://t.co/sqcFBDHSb4

[Warapen Treekit @warapen]

@pedrofsrocha @hospitaldelmar @IMIM_research @AstraZenecaES 👍🏻👍🏻👍🏻

[Vala Afshar @ValaAfshar]

The one thing that only you control is your effort

[Emma Colliver @ColliverEmma]

Fascinating talk from @HansClevers on identifying pks E. Coli mutational signatures in intestinal organoid cultures. Elegant work and beautiful animations alongside. #AACR22

[Immunity @ImmunityCP]

Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox https://t.co/BKrOxMBzxv

[Warapen Treekit @warapen]

@pedrofsrocha Hi Pedro, How is your life at home? Hiro & I are missing you :)

[Warapen Treekit @warapen]

Augmented lipocalin-2 is a molecular feature of COPD-associated LUAD and counteracts LUAD development by maintaining anti-tumor immunity.

https://t.co/JZBSfCDG6r

#lungcancer #COPD #EndCancer
@humam_kadara @AnsamSinjab

[Warapen Treekit @warapen]

@deehk มันเก่าแล้วอ่ะ เห็นว่าจะปรับปรุงใหม่หลายทีแระ คงจะได้ฤกษ์ดีก็คราวนี้